| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 10, 2004
Accepted on February 18, 2005
Fraser Laboratories, Department of Medicine, McGill University, Montreal, QC, Canada. Transgenic Unit, Montreal General Hospital Research Institute, Montreal, QC, Canada. Edison Biotechnology Institute and Department of Biomedical Sciences, College of Osteopapthic Medicine, Ohio University, Athens, OH, USA
* To whom correspondence should be addressed. E-mail: jun-li.liu{at}mcgill.ca.
Both growth hormone and IGF-I stimulate islet cell growth, inhibit cell apoptosis and regulate insulin biosynthesis and secretion. Growth hormone receptor gene deficiency (GHR-/-) caused diminished pancreatic islet cell mass and serum insulin level and elevated insulin sensitivity. As IGF-I gene expression was nearly abolished in these mice, we sought to determine whether that had caused the islet defects. To restore IGF-I level, we have generated transgenic mice that express rat IGF-I cDNA under the direction of rat insulin promoter 1 (RIP-IGF). Using RNase protection assay and immunohistochemistry, the IGF-I transgene expression was revealed specifically in pancreatic islets of the RIP-IGF mice, which exhibited normal growth and development and possess no abnormalities in glucose homeostasis, insulin production and islet cell mass. GHR-/- mice exhibited 50% reduction in the ratio of islet cell mass to body weight, increased insulin sensitivity but impaired glucose tolerance. Compared with GHR-/- alone, IGF-I overexpression on GHR-/- background caused no change in the diminished blood glucose and serum insulin levels, pancreatic insulin contents and insulin tolerance, but improved glucose tolerance and insulin secretion. Remarkably, islet-specific overexpression of IGF-I gene in GHR-/- mice restored islet cell mass, at least partially through cell hypertrophy. Interestingly, male mice of double transgenic demonstrated a transient rescue in growth rates vs. GHR-/- alone, at 2-3 months of age. Our results suggest that IGF-I deficiency is part of the underlying mechanism of diminished islet growth in GHR-/- mice and are consistent with the notion that IGF-I mediate growth hormone-induced islet cell growth.
This article has been cited by other articles:
![]() |
K. Robertson, Y. Lu, K. De Jesus, B. Li, Q. Su, P. K. Lund, and J.-L. Liu A general and islet cell-enriched overexpression of IGF-I results in normal islet cell growth, hypoglycemia, and significant resistance to experimental diabetes Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E928 - E938. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robertson, J. J. Kopchick, and J.-L. Liu Growth hormone receptor gene deficiency causes delayed insulin responsiveness in skeletal muscles without affecting compensatory islet cell overgrowth in obese mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E491 - E498. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |